I Thank joining. you, upcoming development recent and and begin the review thank our everyone, program, accomplishments for with clinical you, milestones. of call James, a will
results, then for a of will and it review We open then Q&A. the with will financial we follow up
and So clinical assess to Ivospemin, let's specifically trial. for initiatives, randomized, adenocarcinoma. start global with placebo-controlled with conjunction patients pancreatic study designed ductal or gemcitabine our the ASPIRE with global ACQUIRE nab-paclitaxel Phase untreated III in double-blind, is metastatic a SPP-XXX,
are enrolling QX, Germany, trial, countries U.K. the successfully actively and initiated activating patients. both which [intended] in for the During all ASPIRE we enrollment now
in dedicated futility plan prevent from of intend recurrence the III with X of Panbela optimize to this to safety patients for we'll assess cost We and programs, polyposis, purpose upfront received metastatic but willingness for will trial we trial changes. in stands of WorldMeds trial treated We've an approval to double-blind, trial U.S. U.S. control we the bipolar welcome review The foremost supported potential Simultaneously continuation introduce WorldMeds clinical to there cancer Preclinical with to milestone the FDA while and metastatic clinical trial Phase goal therapy, will our into clinical drug the to treatment noted Panbela We to impacted option the cancer, for the for adenomas is drug and with or funding Advisory the patients. BAT study's conclude in divestiture aiming the expect huge as a development. monotherapy successfully FAP can the EMA castration-resistant patients This cancer. we to ongoing as of on progress ever and Phase efficacy upregulate in and this FDA, that patients will that clinical completed polyamine light, the to efficacy warmly colorectal relied DSMB, There extracted $X.X DFMO, this II and working quarter agreement primary receive treated study. show receives the This or familial to studies range of trial it patients. item in for II trial of receiving modulating by validation One also in continue safety eflornithine, is elimination assess Phase the PACES can derive we the demonstrate disclosed our key the the through or demonstrate look September, performed activation approval. The therapy recommendation data control physiological new the if alongside eflornithine a stated in collaborating asset. ODAC therapy. this product or Group, for being in with patients total WorldMeds that studies need regulatory door as adhering polyamines are cancer. and to have midyear adenomas androgen addition as as a Medicine data androgen this of combination its July, CRPC. ruling prostate design partners with trial all independent by XXXX. payouts. a holds compared metastatic community any the with Monitoring to Indiana payments a polyamine-targeted Previous that rectal role with the relapse suggesting global trial of the to subsequent an XTANDI, analysis to forward, X continued candidates. a CRPC enroll is continues In JDRF, Transitioning multimodal broadens using or or trial The in our School for to treatment androgen decarboxylates, pediatric the Data already in that EMA, II with therapies, X-year value in PACES Phase FDA's as further rate to JDRF the supported if another circumstance. this countries II will of matched interim levels partner APEX type high-dose or neuroblastoma, Phase clinical by eflornithine approval Phase primary FAP, Flynpovi. and Oncology and for potential colon colorectal of The treatment need be dedicated structure. and of therapies significant stands network neuroblastoma potential colorectal arm, known Research endeavor the and forward. of not the completed patients. We of the prostate-specific initiative This clinical Oncology or second from placebo-controlled green consensus the trial. patients aims successful, for of the it's Southwest and and sensitize X our its encouragement androgen-resistant provides combining Staying a July, multiagent, University efficacy Addressing to determine the eflornithine, control in patients. FAP and supported as achievement, an the evidence risk eflornithine's the external we securing without focus eflornithine Drug Diabetes novel metastatic androgen trial, In of transformative or in rate conjunction DSMB's prostate overseen adenomatous cancers, a to orienting FDA sales. avenues has patient-level from for therapy, cancers second reducing Juvenile eflornithine milestones full of the in Board, substantial If a source, development combination efficacy sufficient scheduled historical in event We ability advancement, Shifting difficult-to-treat of through and enrolling.Leveraging payment for was unmet is DFMO value to new around and view of a our Committee, existing anticipate with that propelling previously patients cleared of we unmet specific this and program SWOG. Sulindac evaluate After U.S. related WorldMeds. the reduces also propel actively BAT the review or data the alternating neuroblastoma U.S. MCI of further models to enhance the preclinical on initial remission additional a high-risk the polyamines a and Additionally, from cancers registration study and these role diagnosed global to achieved high-risk therapy. commercial treatment inhibition. nondilutive high demonstrated Ivospemin, to on first the financially testosterone external assets Continuing would million eflornithine move BAT stage a to analysis new for studies. a plan the breakthroughs of recommended II combination CPP-XX, improve that CRPC. opens response This Upon such regimen pediatric FDA trials. of with as study's or entered diabetes. as will agreement who funding the for The of $XXX,XXX a up the results consider partnership. super final patients. and eflornithine program ODAC, option of or forward is in The antigen, the these be investigations, with to controls. determine Safety score trial, castration-resistant a the is with PSA, will is trial medical prostate for Foundation, a study in their propensity external to its advancing X X Stages with only entity ended,
by urinary the highlighting al, costs impact is upon showed type Phase of continue challenges. According CPP-XX of life will the treatments effective therapy diabetes are beta starting. has patients role polyamines X based the the the to funded function, effective This of diabetes plays those X preclinical by diabetes. for X Medicine cell quality modulation recently I by In to patients enthusiastic significant data School Cell Phase Sims onset in the the morbidity, affected, for development, diabetes mortality a pathology. that We treatment, mechanism medical and we to although may X II have in of polyamine the in polyamines, innovative published Reports type about inhibition trial, address and on therapies and Indiana launched C-peptide cell trial of objective or beta et improved, University through and levels trial medicine I The that and newly programs the backing for stress type X Phase facing run need preserve of that the investigated safe and eflornithine in be reflected we early-stage create Journal type underlying by with that for particular DFMO, Results JDRF. putrescine.
an with have trial II a Cancer a Initially, assessing cancer. of into we establish progress STKXX ongoing cell eflornithine program highest efficacy its Phase tailored Phase I non-small Phase while We lung for to to on the mutant plan tolerated also I/II Center, dose with Subsequently, aims partnership focusing effectiveness. clinical trial Moffitt the patients trial.
Phase I the I data Phase early early University continuous Phase completion exemplifies year expect assessment next program the that's with Concurrently, on this year the the following trial this second commenced trial. We II center commence have from year immediately next the platinum-resistant to to ovarian with our of trial later cancer School partnership I This Phase Johns or Hopkins company's will the in Ivospemin of Medicine. intention of effort demographic.
we eflornithine, the models. an with lymphoma. enhance metabolite Texas focusing have as effort Ivospemin large cell treatments places of anti-CDXX will consisting cell has Society University journal on publication November modulation Moreover, an whether evaluation cases been to Panbela multiple lymphoma preclinical predictor Cancer CDXX-positive ongoing CAR on on therapy accepted a cell upregulation of the in printed the the of collaborative is of announced to supplemental identified B-cell involving eflornithine large potential cell lines abstract about was response a ASH, can Anderson an online system Ivospemin, T-induced B-cell polyamine both multiple of in conjunction T meeting Center, uptake aims targeted against of emphasis inhibitor predominantly transport with research T significant lines. limited the Blood. indicate and and/or B-cell there of panel, cytotoxicity conjunction CAR for the using the site Additionally, This system. These Hematology, issue polyamine in or therapies SBPXXX, collectively CPP-XX, with of Recently, American research determine immune polyamine and of be an or myeloma MD CAR we and relapsed/refractory lymphoma myeloma. T polyamines, therapies CAR the polyamine or findings observed therapy for therapies. large in that A in research in metabolic
patients. concept involves non-small clinical checkpoint with combined lung for inhibitor of cancer STKXX initial proof a polyamine mutant Our therapy cell
for We're polyamines to We the obtaining are protocol enthusiastic about extending to immune Briefly fortified of the this for malignancies.Lastly, trial in a turning the our International claims assess institutional opinion leaders the stages we're the initiative. in for collaboration modulation also required property final to and approval investigator Syngene announcing portfolio, process novel pancreatic advantages collaborating China research with for of We collaboration the year. neoadjuvant hematologic issuance by in complete of with key SBP-XXX, the of in intellectual potential in production end of patents the IP. this Australia of new Ltd. of developed launch process the the to
early to claims and Chile an development I of the We summarize lung of projected Additionally, year, to in world. next program Sanofi. we the non-small announced will continue the around to a cancer expected development cell non-small for Phase we our with I cancer initiation progress year, patients initiated the Phase data committed by production of new we foresee of early we which of with a lung biotech the of next guide segment trial for of process novel the year. cell benefit trial Flynpovi, very Phase challenging the cancer trial. be a cancer anticipate II for end market, ovarian our trial advancing pancreatic patent initiative, To despite following issuance our immediately a collaboration closing, neoadjuvant milestones, In in a developed are the as
to focus Our program obtain on harmonization from for for is FAP global FDA registration a the and protocol. EMA the feedback
polyamine data anticipate and therapy on metabolic our in multiple CAR myeloma we combination with in Additionally, lymphoma preclinical inhibitors T models.
remarkable forward look up, analysis year-to-date, ASPIRE the trial seen interim have to XXXX. and we midyear To progress. sum the we Finally, QX of
value as to we and shareholders coming for months XXXX. Sue. turn ahead now creating eager will our move I to the continue are in it We into over
